Bio Therapeutic Drug Business Investment Opportunities

Planning to establish a cannabis plantation to produce anesthetic drugs. - Seeking foreign investors to comply with the local law, which mandates that only foreigners can hold a license for cannabis plantations. - The promoter is an Ayurvedic doctor with 30 years of experience in the industry. - We will be applying for licenses, and only foreigners are eligible to hold them. - Our plan is to establish a cannabis plantation and export cannabis anesthetic drugs through distributors worldwide. - The drugs will be specifically formulated for anesthesia purposes.

High potential company with a science-proven, patented beverage for acute alcohol intoxication. - Our product is a science-based beverage designed for the resolution of acute alcohol toxicity. - The company has developed this product over the past 3 years and is now seeking early-stage investors to bring it to market. - We are in discussions with approximately 18 major clients in the pharmaceutical industry, including pharma product buyers and large pharmacies such as Audifarma and Eticos Serrano, to ensure effective product introduction and distribution. - Our team has over 4 years of successful experience in launching pharmaceutical products in the Colombian market. - We will be available in the market in the next few months. - Our target audience is the alcohol consumption market, focusing on providing a solution for alcohol elimination in intoxicated individuals. - The company is currently in the pre-seed stage. - We are planning to establish a manufacturing unit soon, with a production capacity of 100,000 units per month. - Company has incorporation license and INVIMA registration (license from the National Food and Drug Surveillance Institute)

The company is a pharmaceutical and healthcare business based in Cambridge, specializing in drug discovery and development of novel drug compounds. - The company has a small team of 5 employees, with promoters who have over two decades of experience in pharmacology, having worked as scientists at renowned universities in the United Kingdom. - The company's research and development infrastructure is well-established, and it also offers managed print services and contract research in addition to drug development. - The focus of the company's research is on finding a cure for Parkinson's disease, with over 130 tests conducted on the drug compound showing a 75% success rate, with an expected increase to over 90% within the next 2 years. - Upon launch to the public, the company anticipates generating over 90% in profits. - The company's drug discovery and development process is supported by Indian scholar scientists based in the UK, adding a diverse and skilled team to its research efforts. - All research documents related to the drug compounds and trials are available for review, providing transparency and insight into the company's research and development activities.

The company is a pharmaceutical and healthcare business based in Cambridge, specializing in drug discovery and development of novel drug compounds. - The company has a small team of 5 employees, with promoters who have over two decades of experience in pharmacology, having worked as scientists at renowned universities in the United Kingdom. - The company's research and development infrastructure is well-established, and it also offers managed print services and contract research in addition to drug development. - The focus of the company's research is on finding a cure for Parkinson's disease, with over 130 tests conducted on the drug compound showing a 75% success rate, with an expected increase to over 90% within the next 2 years. - Upon launch to the public, the company anticipates generating over 90% in profits. - The company's drug discovery and development process is supported by Indian scholar scientists based in the UK, adding a diverse and skilled team to its research efforts. - All research documents related to the drug compounds and trials are available for review, providing transparency and insight into the company's research and development activities.

A biotech firm based in Milan, focusing on cancer immuno personalized therapy. - Has a portfolio of R&D projects and two Finished Dosage Forms (FDF) in the Italian market, including Aripiprazole and Emtricitabine + Tenofovir. - The company specializes in the development of microfluidic technology for the production and purification of Exosomes, with applications in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments. - Exosomes, a key product of the company, are body-identical ingredients known for their high stability and low likelihood of causing adverse reactions. Their cell-penetrating mechanism enables them to deliver regeneration signals, making them suitable for diverse medical and cosmetic applications. - Has 3 major clients and supplied on a quarterly basis to pharmaceutical companies in Italy, Poland, and Brazil. - Operates with a network of 12 agents in addition to its 3 permanent employees. - Collaborates with Contract Manufacturing Organizations (CMOs) for the production of its pharmaceutical products. The company holds essential regulatory licenses from GMP, FDA, and the Ministry of Health, ensuring compliance with international quality and safety standards.

Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing. - Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process. - A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions. - Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine. - Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept. - Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc. - Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients. - Positioned in the $300 billion back pain industry, addressing a significant market need. - Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development. - Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility. - Founded by individuals with decades of experience in the industry.

We have launched 15 innovative products. The products are planned for sales through omni channel marketing. We have presence in general trade and ecommerce. We need to enter into exports, modern trade and multiple market places. .

We are a biopharma company dealing in the research and development of various formulations and clinical trials. - As of now the company has rights of 15 formulations and has a large market share in this industry. - Our company has two revenue models. We treat patients majorly from the countries such as Australia, Canada, and the USA using our technology. - These patients especially travel to India for our treatments. - We don't have our own clinics but subcontract hospitals in Mumbai to use our technology. - Another revenue source is to supply our formulations and technology to various other hospitals & clinics and receive a royalty from them. - We also have discussions going on with various insurance companies to provide coverage for our treatments. - Since the majority of our clients are from the USA we are planning to start a drug manufacturing unit there. - This unit will be under the USFDA regulations which would increase our scope to expand into various other international markets. - The company has two partners with a 70% and 30% stake distribution. - Business has not taken any loans previously. - We are seeking investment to establish the manufacturing unit.